Legacy Wealth Management LLC MS Sells 20,332 Shares of Agilent Technologies, Inc. $A

Key Points

• Legacy Wealth Management LLC significantly reduced its stake in Agilent Technologies by 74.7%, selling 20,332 shares and holding 6,873 shares valued at $811,000.
• CEO Padraig Mcdonnell sold 1,508 shares at an average price of $117.44, resulting in a 3.87% decrease in their position.
• Agilent Technologies reported earnings of $1.37 EPS for the last quarter, matching analysts' expectations, with a revenue increase of 10.1% year-over-year.

Legacy Wealth Management LLC MS cut its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 74.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,873 shares of the medical research company's stock after selling 20,332 shares during the quarter. Legacy Wealth Management LLC MS's holdings in Agilent Technologies were worth $811,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Agilent Technologies by 13.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after buying an additional 4,362 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Agilent Technologies by 8.3% in the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after buying an additional 2,371 shares during the period. Alps Advisors Inc. increased its stake in shares of Agilent Technologies by 29.5% in the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock valued at $1,563,000 after buying an additional 3,040 shares during the period. D.A. Davidson & CO. increased its position in Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after purchasing an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. increased its position in Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after purchasing an additional 54,302 shares during the period.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer directly owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Agilent Technologies Trading Up 1.2%

Shares of A stock traded up $1.55 during trading hours on Tuesday, hitting $127.18. 1,710,018 shares of the company were exchanged, compared to its average volume of 1,743,662. The firm has a market cap of $36.06 billion, a P/E ratio of 23.05, a P/E/G ratio of 3.91 and a beta of 1.24. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The company has a 50 day simple moving average of $119.89 and a two-hundred day simple moving average of $115.77.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company's quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on A. UBS Group decreased their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research report on Thursday, May 29th. Robert W. Baird increased their target price on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Wells Fargo & Company increased their target price on shares of Agilent Technologies from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Monday. Wall Street Zen downgraded shares of Agilent Technologies from a "buy" rating to a "hold" rating in a research report on Friday, September 5th. Finally, Barclays reissued an "equal weight" rating and set a $125.00 target price on shares of Agilent Technologies in a research report on Friday, August 29th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and an average target price of $140.08.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.